JenaValve
Irvine, California, United States · Biotechnology, Healthcare, Health Care
JenaValve is a medical device company developing the first transcatheter heart valve technology that is uniquely designed for the minimally invasive treatment of aortic regurgitation (AR). The JenaValve Trilogy Heart Valve System is the first and only device currently approved in the EU for the treatment of severe, symptomatic aortic regurgitation in patients that are deemed high-risk for surg
Key facts
- Headquarters
- Irvine, California, United States
- Employees
- Unknown
- Industries
- Biotechnology, Healthcare, Health Care
- Status
- Private
- Website
- jenavalve.com
- Company page
Recent activity at JenaValve
- : JenaValve Appoints Edward Sarnowski as Chief Technology Officer
- : JenaValve Technology
- : Jenavalve Raises $100 Million To Advance Trilogy Tavr Solution
- : JenaValve Technology Inc
- : JenaValve Technology Inc
- : JenaValve Technology Inc
- : JenaValve Technology Inc
- : JenaValve Technology Inc
- : JenaValve Technology Inc
- : JenaValve Technology Inc
JenaValve funding history
| Date | Round | Amount |
|---|---|---|
| Apr 2024 | Venture | $100.4M |
| Aug 2022 | Funding Round | $100.0M |
| Jan 2022 | Venture | $100.4M |
| Oct 2020 | Venture | $66.5M |
| Feb 2020 | Venture | $35.5M |
Leadership
- John Kilcoyne, CEO
- John Kilcoyne, Executive Officer, Director
- John Kilcoyne, Executive Officer, Director
- Jan Keltjens, Director
- Keith Dawkins, Director
- Andrew Hack, Director
- Olivier Litzka, Director
- Erik Amble, Director
- Patrick Beneden, Director
- Jose Gordo, Director
- Rudi Marien, Director
- Rudi Marien, Director
Verified email and direct lines for JenaValve’s decision-makers are on Fundz. See plans
JenaValve in the news
- JenaValve data backs Trilogy TAVR in AR, LVAD patients - MassDevice (Jul 01, 2026)
- FDA Approves JenaValve’s Trilogy for Aortic Regurgitation - TCTMD.com (Mar 23, 2026)
- JenaValve's Trilogy valve secures FDA's 1st approval in aortic regurgitation - Fierce Biotech (Mar 18, 2026)
- Edwards Comments on JenaValve Acquisition - Business Wire (Jan 09, 2026)
- US FTC wins ruling blocking Edwards Lifesciences' acquisition of JenaValve - Reuters (Jan 09, 2026)
- FTC wins case blocking Edwards' $945M JenaValve takeover - Fierce Biotech (Jan 12, 2026)
- FTC Files Lawsuit to Block Edwards Lifesciences’ Purchase of JenaValve Technology - WSJ (Aug 06, 2025)
- Commissural Alignment After Transfemoral Transcatheter Aortic Valve Replacement With the JenaValve Trilogy System - JACC Journals (Sep 20, 2021)
Companies similar to JenaValve
- Dror Ortho-Design · Biotechnology, Healthcare, Health Care, Information Technology, Manufacturing, Medical Device
- Ionetix Corp · Biotechnology, Healthcare, Health Care, Manufacturing, Medical Device
- RIVANNA · Biotechnology, Healthcare, Health Care, Manufacturing, Medical Device
- Monogram Technologies · Biotechnology, Health Care, Information Technology, Manufacturing, Medical Device
- SynerFuse, Inc. · Biotechnology, Healthcare, Health Care, Manufacturing, Medical Device
About JenaValve: questions and answers
What does JenaValve do?
JenaValve is a medical device company developing the first transcatheter heart valve technology that is uniquely designed for the minimally invasive treatment of aortic regurgitation (AR). The JenaValve Trilogy Heart Valve System is the first and only device currently approved in the EU for the treatment of severe, symptomatic aortic regurgitation in patients that are deemed high-risk for surg
Where is JenaValve headquartered?
JenaValve is headquartered in Irvine, California, United States.
Has JenaValve raised funding?
Yes. Fundz has recorded 5 funding events for JenaValve. The most recent, $100.4M, was in Apr 2024.
Who leads JenaValve?
John Kilcoyne is a CEO at JenaValve.
What is the latest news on JenaValve?
On May 28, 2026, JenaValve Appoints Edward Sarnowski as Chief Technology Officer
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy